FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307208518> ?p ?o ?g. }

• W4307208518 endingPage "243" @default.
• W4307208518 startingPage "233" @default.
• W4307208518 abstract "Abstract Purpose: To date, there are no systemic treatment options for patients with recurrent or refractory meningioma. Experimental Design: To identify effective drugs, we performed a large-scale drug screening using FDA-approved drugs on several meningioma cell lines. The impact of the top four compounds was assessed on cell viability, proliferation, colony formation, migration, and apoptosis. In addition, the antineoplastic effects of the selected drugs were validated in a heterotopic xenograft mouse model. Results: Analyses of the viability of meningioma cells treated with 119 antineoplastic FDA-approved drugs resulted in categorization into sensitive and resistant drug–response groups based on the mean IC50 values and peak serum concentrations (Cmax) in patients. Eighty drugs, including 15 alkylating agents, 14 antimetabolites, and 13 tyrosine kinase inhibitors, were classified as resistant (IC50 &gt; Cmax). The sensitive drug–response group (n = 29, IC50 &lt; Cmax) included RNA/protein synthesis inhibitors, proteasome inhibitors, topoisomerase, tyrosine-kinase, and partial histone deacetylase and microtubule inhibitors. The IC50 value of the four most effective compounds (carfilzomib, omacetaxine, ixabepilone, and romidepsin) ranged from 0.12 to 9.5 nmol/L. Most of them caused cell-cycle arrest in the G2–M-phase and induced apoptosis. Furthermore, all drugs except romidepsin significantly inhibited tumor growth in vivo. The strongest antineoplastic effect was observed for ixabepilone, which reduced tumor volume by 86%. Conclusions: In summary, a large-scale drug screening provides a comprehensive insight into the anti-meningioma activities of FDA-approved drugs, and identified carfilzomib, omacetaxine, ixabepilone, and romidepsin as novel potent antineoplastic agents for the treatment of aggressive meningiomas. The most pronounced effects were observed with ixabepilone mandating for further clinical investigation." @default.
• W4307208518 created "2022-10-30" @default.
• W4307208518 creator A5014073957 @default.
• W4307208518 creator A5014216255 @default.
• W4307208518 creator A5025477516 @default.
• W4307208518 creator A5047106375 @default.
• W4307208518 creator A5055005604 @default.
• W4307208518 creator A5063504569 @default.
• W4307208518 creator A5068781838 @default.
• W4307208518 creator A5070176744 @default.
• W4307208518 creator A5075116222 @default.
• W4307208518 creator A5085166299 @default.
• W4307208518 date "2022-10-25" @default.
• W4307208518 modified "2023-10-01" @default.
• W4307208518 title "Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas" @default.
• W4307208518 cites W1754300748 @default.
• W4307208518 cites W1973762438 @default.
• W4307208518 cites W1985773289 @default.
• W4307208518 cites W1985864219 @default.
• W4307208518 cites W1988927456 @default.
• W4307208518 cites W1995312162 @default.
• W4307208518 cites W1997207651 @default.
• W4307208518 cites W2016912869 @default.
• W4307208518 cites W2027675488 @default.
• W4307208518 cites W2034972449 @default.
• W4307208518 cites W2042799451 @default.
• W4307208518 cites W2051257692 @default.
• W4307208518 cites W2060724712 @default.
• W4307208518 cites W2074400892 @default.
• W4307208518 cites W2103580195 @default.
• W4307208518 cites W2118302917 @default.
• W4307208518 cites W2123099447 @default.
• W4307208518 cites W2128725138 @default.
• W4307208518 cites W2130794506 @default.
• W4307208518 cites W2136905052 @default.
• W4307208518 cites W2146502430 @default.
• W4307208518 cites W2234203939 @default.
• W4307208518 cites W2328292414 @default.
• W4307208518 cites W2366536035 @default.
• W4307208518 cites W2426305918 @default.
• W4307208518 cites W2469735602 @default.
• W4307208518 cites W2514454733 @default.
• W4307208518 cites W2600231501 @default.
• W4307208518 cites W2725132978 @default.
• W4307208518 cites W2807218055 @default.
• W4307208518 cites W2899552791 @default.
• W4307208518 cites W2901716885 @default.
• W4307208518 cites W2912957649 @default.
• W4307208518 cites W2933761349 @default.
• W4307208518 cites W2961400149 @default.
• W4307208518 cites W2971441574 @default.
• W4307208518 cites W2971941127 @default.
• W4307208518 cites W3043656036 @default.
• W4307208518 cites W3095210345 @default.
• W4307208518 cites W3126252440 @default.
• W4307208518 cites W3135274341 @default.
• W4307208518 cites W3172177665 @default.
• W4307208518 cites W3183016552 @default.
• W4307208518 cites W3216745368 @default.
• W4307208518 cites W4211132876 @default.
• W4307208518 doi "https://doi.org/10.1158/1078-0432.ccr-22-2085" @default.
• W4307208518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36282277" @default.
• W4307208518 hasPublicationYear "2022" @default.
• W4307208518 type Work @default.
• W4307208518 citedByCount "6" @default.
• W4307208518 countsByYear W43072085182023 @default.
• W4307208518 crossrefType "journal-article" @default.
• W4307208518 hasAuthorship W4307208518A5014073957 @default.
• W4307208518 hasAuthorship W4307208518A5014216255 @default.
• W4307208518 hasAuthorship W4307208518A5025477516 @default.
• W4307208518 hasAuthorship W4307208518A5047106375 @default.
• W4307208518 hasAuthorship W4307208518A5055005604 @default.
• W4307208518 hasAuthorship W4307208518A5063504569 @default.
• W4307208518 hasAuthorship W4307208518A5068781838 @default.
• W4307208518 hasAuthorship W4307208518A5070176744 @default.
• W4307208518 hasAuthorship W4307208518A5075116222 @default.
• W4307208518 hasAuthorship W4307208518A5085166299 @default.
• W4307208518 hasConcept C104317684 @default.
• W4307208518 hasConcept C121608353 @default.
• W4307208518 hasConcept C126322002 @default.
• W4307208518 hasConcept C185592680 @default.
• W4307208518 hasConcept C2775930923 @default.
• W4307208518 hasConcept C2776364478 @default.
• W4307208518 hasConcept C2777478702 @default.
• W4307208518 hasConcept C2778305200 @default.
• W4307208518 hasConcept C2779194965 @default.
• W4307208518 hasConcept C2780108899 @default.
• W4307208518 hasConcept C2781462825 @default.
• W4307208518 hasConcept C530470458 @default.
• W4307208518 hasConcept C55493867 @default.
• W4307208518 hasConcept C64927066 @default.
• W4307208518 hasConcept C71924100 @default.
• W4307208518 hasConcept C98274493 @default.
• W4307208518 hasConceptScore W4307208518C104317684 @default.
• W4307208518 hasConceptScore W4307208518C121608353 @default.
• W4307208518 hasConceptScore W4307208518C126322002 @default.
• W4307208518 hasConceptScore W4307208518C185592680 @default.
• W4307208518 hasConceptScore W4307208518C2775930923 @default.

• next